ORTEXORTEX News
Live short interest, options flow, and signals — free on ORTEX.Sign up free →
Market Commentary

Shenzhou Chairman Buys $45M as Asian Insiders Signal Confidence

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 1 min read

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

The most striking insider buying in recent filings comes from outside the US. Ma Jianrong, Executive Chairman of Shenzhou International Group, filed a cluster of open-market purchases totalling roughly $45m across four days in early September. He bought 5.6 million shares on 1 September at a disclosed value of $25.8m, followed by further tranches on 2, 3 and 4 September worth a combined $19m. These were discretionary purchases, not compensation awards, making them a stronger conviction signal.

In Thailand, Nualphan Lamsam, CEO of Muang Thai Insurance, filed two separate buys totalling $7.4m over consecutive trading days in early September, picking up more than 12.9 million shares at market prices.

Turkey also saw notable activity. Serdar Turhan, Executive Chairman of Katilimevim Tasarruf Finansman, accumulated shares across multiple sessions totalling more than $47m in aggregate filed purchases between 1 and 3 September, a concentrated buying spree that stands out in size and pace.

On the sell side, the CEO of South Korean robotics company ROBOTIS filed a $75m disposal of 366,525 shares on 8 September, a large reduction relative to typical insider trade sizes in that market.

One note on scope: the US SEC EDGAR Form 4 tables were not accessible via the available SQL interface, so the article draws on vendor data for non-US markets only. Fresh US insider filings could not be retrieved for this edition.

Stocks in this article

How this article was generated

Generated
23 Oct 2026, 04:12
Prompt version
v1.0
Data sources
Institutional positioningAlt DataIndex Rebalance

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.